irinotecan liposome HR070803
Term · Oncology and biomedicine · MLC-T-ONC-014575
A liposomal formulation of the semisynthetic camptothecin analogue irinotecan, with potential antineoplastic activity. Upon administration of irinotecan liposome HR070803, irinotecan selectively stabilizes topoisomerase I-DNA covalent complexes during the S phase of the cell cycle, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell.
| Identifier | MLC-T-ONC-014575 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | liposomal irinotecan HR070803 |
| References | National Cancer Institute Thesaurus (CC BY 4.0) |
Record as JSON
{
"id": "MLC-T-ONC-014575",
"term": "irinotecan liposome HR070803",
"field": "Oncology and biomedicine",
"definition": "A liposomal formulation of the semisynthetic camptothecin analogue irinotecan, with potential antineoplastic activity. Upon administration of irinotecan liposome HR070803, irinotecan selectively stabilizes topoisomerase I-DNA covalent complexes during the S phase of the cell cycle, inhibiting religation of topoisomerase I-mediated single-strand DNA breaks and producing lethal double-strand DNA breaks when complexes are encountered by the DNA replication machinery. Liposome encapsulation of this agent promotes efficient drug delivery into the cytosol from the endosome compartment of the cell.",
"synonyms": [
"liposomal irinotecan HR070803"
],
"references": [
"National Cancer Institute Thesaurus"
],
"url": "https://mlchart.com/terminology/oncology/irinotecan-liposome-hr070803/"
}
Record 9,576 of 17,721 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.